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Summary: Educational reforms over a century ago established a the-
ory to practice undergraduate medical curriculum design, in which 
“theory” equated with biomedical science. It is remarkable that a 
theory of professional knowledge that is so old has been so little 
challenged. We continue to assume that mastery of a rather limited 
canon of knowledge will lead inductively to practical competence and 
are surprised and disappointed when it does not. Donald Schön has 
written about the tension between the “high ground” of the universi-
ties and the “swampy lowlands” of practice. Gradually, the swampy 
lowlands have gained scholarly credibility, and a tension is becoming 
apparent between the competence that is needed to be an effective 
practitioner and the competencies that are taught in universities. 
Yet, there is a common desire that medicine should be a scholarly 
discipline. This presentation explores how theory and practice can 
best be integrated in the education of safe and effective practitioners. 
It draws on theories of training design and observational research 
into how medical students prepare for transition to residency. It aims 
to answer the question “how can medical students best prepare to 
prescribe effectively after starting their careers as doctors”?
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Summary: Up to 60% of depressed patients do not respond com-
pletely to antidepressants (ADs) and up to 30% do not respond at 
all. Genetic factors contribute for ~50% of the AD response. During 
recent years, the possible influence of a set of candidate genes as 
genetic predictors of AD response efficacy was investigated by us 
and others. They include the cytochrome P-450 superfamily, the 
P-glycoprotein (ABCB1), the tryptophan hydroxylase, the catechol-
O-methyltransferase, the monoamine oxidase A, the serotonin trans-
porter (5-HTTLPR), the norepinephrine transporter, the dopamine 
transporter, variants in the 5-hydroxytryptamine receptors (5-HT1A, 
5-HT2A, 5-HT3A, 5-HT3B, and 5-HT6), adrenoreceptor β -1 and 
α -2, the dopamine receptors (D2), the G protein β 3 subunit, the 
corticotropin-releasing hormone receptors (CRHR1 and CRHR2), 
the glucocorticoid receptors, the c-AMP response-element binding, 
and the brain-derived neurotrophic factor. Marginal associations 
were reported for angiotensin I–converting enzyme, circadian loco-
motor output cycles kaput protein, glutamatergic system, nitric oxide 
synthase, and interleukin 1-β gene. In conclusion, gene variants seem 
to influence human behavior, liability to disorders, and treatment 
response. Nonetheless, gene × environment interactions have been 
hypothesized to modulate several of these effects.
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Summary: The advances in genetics and informatics have stimu-
lated research involving biobanks. Research using samples and data 
involves privacy risks. Identifiability and its degrees have implications 
on determining the risk/benefit ratio of a research project. Although 
the need to protect confidentiality and to put in place security meas-
ures is widely recognized, terminological confusion and philosophical 
differences dominate the ethical and legal discussion about confi-
dentiality of data and samples. Different mechanisms, such as cod-
ing or anonymization, influence not only privacy risks of those who 
supplied the biological samples but also determine whether it will 
be possible to communicate the results of any genetic analysis back 
to the research participants. Moreover, it is generally admitted that 
donors have the right to opt out of a biobank. This means that they 
may ask for destruction or unlinked anonymization of samples and 
data. Both can only be carried out if a link is kept between the donors 
and their samples and data.
In this presentation, different strategies of anonymization and 
coding will be described and ethical and legal arguments in favor 
and against them will be discussed, based on the framework of inter-
national ethical guidance and human rights implemented in Europe.
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Summary: The European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP), coordi-
nated by the European Medicines Agency, has seen rapid growth 
in recent years and now accounts for > 170 partner organizations, 
including research centers, therapeutic networks, and data source 
owners. The increase in pharmacoepidemiology research via net-
works such as ENCePP is a clear trend to make best use of available 
data and expertise, through the conduct of high-quality, independ-
ent, and transparent studies focusing on safety and on benefit/risk. 
Through ENCePP, there is an enhanced capacity to plan and per-
form postauthorization studies that are essential to the monitoring 
of safety and efficacy of medicines throughout the product lifecycle.
In addition to increasing capacity for important observational 
research as requested by regulatory authorities and providing a read-
ily available pool of pharmacoepidemiology expertise, ENCePP has 
been instrumental in developing tools that translate guiding princi-
ples into research practice. The network’s outputs include a Code 
of Conduct, a guide on methodologic research standards, and a 
Checklist for Study Protocols. These are all cited in the recently pub-
lished module VIII of Good Vigilance Practice on PASS. A database 
of studies developed through ENCePP is currently serving as the EU 
PAS Register, where companies register their PASS in compliance 
with the provisions on transparency in the new PhV legislation. 
The EU PAS Register welcomes registration of studies conducted 
worldwide.
Current opportunities for the network include sourcing of sus-
tainable funding for the partner organizations and existing networks 
involved, perceived barriers to sharing of data for studies applying 
for an ENCePP Study Seal, and extension of the network to research 
centers outside of the EU. Overcoming these challenges is important 
to the continued success of the network.
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Summary: Mediator® (benfluorex), a French and worldwide public 
health disaster
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Benfluorex (brand names Mediator®, Mediaxal® , Lipascor®; 
drug company Servier) was marketed in France and worldwide until 
2009. This marketing authorization was held while the  compounds 
